Literature DB >> 6134538

Depression of nociceptive sympathetic reflexes by the intrathecal administration of midazolam.

D Niv, J G Whitwam, L Loh.   

Abstract

The effect of the intrathecal administration of midazolam 0.5-1.0 mg in 1-2 ml of physiological saline solution, has been observed on responses evoked in renal sympathetic nerves by supramaximal electrical stimulation of radial and tibial nerves. In artificially ventilated dogs anaesthetized with alpha-chloralose, the intrathecal administration of midazolam caused a marked depression of reflexes evoked from the tibial nerve but had no effect on either spontaneous sympathetic activity or reflexes evoked by radial nerve stimulation. Neither the small amount (1-2 microliters) of benzyl alcohol, present as a preservative (administered intrathecally), nor midazolam 1 mg kg-1 i.v. caused any significant depression of the evoked somato--sympathetic reflexes. The effects of intrathecal midazolam were reversed by the benzodiazepine antagonists Ro 15-1788 1 mg kg-1 i.v. and Ro 15-3505 1-2 mg kg-1 i.v. but not by naloxone 2 mg i.v. It is suggested that the antinociceptive effect of locally applied midazolam could be the result of a non-opioid GABA-mediated system which may have implications in the management of pain.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134538     DOI: 10.1093/bja/55.6.541

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  11 in total

1.  GABAergic modulation of diffuse noxious inhibitory controls (DNIC): a test by use of lorazepam.

Authors:  Miriam Kunz; Kirsten Elisabeth Scholl; Ulrich Schu; Stefan Lautenbacher
Journal:  Exp Brain Res       Date:  2006-07-01       Impact factor: 1.972

2.  Evidence for an excitatory action of the benzodiazepine receptor inverse agonist FG 7142 on C-fibre afferents.

Authors:  J Donnerer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

3.  A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia.

Authors:  Francis Codero; Mung'ayi Vitalis; Sharif Thikra
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

4.  Effects of an intrathecally administered benzodiazepine receptor agonist, antagonist and inverse agonist on morphine-induced inhibition of a spinal nociceptive reflex.

Authors:  J L Moreau; L Pieri
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

5.  Attenuation of reperfusion hyperalgesia in the rat by systemic administration of benzodiazepines.

Authors:  S M Cartmell; D Mitchell
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Ethanol Increases Mechanical Pain Sensitivity in Rats via Activation of GABAA Receptors in Medial Prefrontal Cortex.

Authors:  Kai-Wen Geng; Ting He; Rui-Rui Wang; Chun-Li Li; Wen-Jun Luo; Fang-Fang Wu; Yan Wang; Zhen Li; Yun-Fei Lu; Su-Min Guan; Jun Chen
Journal:  Neurosci Bull       Date:  2016-09-15       Impact factor: 5.203

7.  The effects of intrathecal midazolam on sympathetic nervous system reflexes in man--a pilot study.

Authors:  C S Goodchild; J Noble
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

8.  [Intrathecal and epidural administration of non-opioid analgesics in acute and chronic pain treatment.].

Authors:  B Donner; M Tryba; M Zenz; M Strumpf
Journal:  Schmerz       Date:  1994-06       Impact factor: 1.107

Review 9.  Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

Authors:  Joël Schlatter; David Nguyen; Michèle Zamy; Sofiane Kabiche; Jean-Eudes Fontan; Salvatore Cisternino
Journal:  Eur Spine J       Date:  2017-11-18       Impact factor: 3.134

10.  Midazolam for caudal analgesia in children: comparison with caudal bupivacaine.

Authors:  M Naguib; M el Gammal; Y S Elhattab; M Seraj
Journal:  Can J Anaesth       Date:  1995-09       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.